SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 81.50 |
| Enterprise Value ($M) | 42.55 |
| Book Value ($M) | 51.18 |
| Book Value / Share | 1.95 |
| Price / Book | 1.59 |
| NCAV ($M) | 48.37 |
| NCAV / Share | 1.84 |
| Price / NCAV | 1.69 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.73 |
| Return on Assets (ROA) | -0.31 |
| Return on Equity (ROE) | -0.56 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.62 |
| Current Ratio | 6.62 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 98.90 |
| Assets | 101.71 |
| Liabilities | 50.53 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 6.77 |
| Operating Income | -43.25 |
| Net Income | -41.97 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -38.97 |
| Cash from Investing | -17.64 |
| Cash from Financing | -0.57 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Novo Holdings A/S | 0.00 | -100.00 | |
| 13G/A | Redmile Group, LLC | 7.90 | -26.34 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 8,332 | 45,783 | 18.20 | |
| 11,336 | 8,510 | 133.21 | |
| 25,146 | 46,651 | 53.90 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| KURA – Kura Oncology, Inc. | KYTX – Kyverna Therapeutics, Inc. |
| KZR – Kezar Life Sciences, Inc. | LXRX – Lexicon Pharmaceuticals, Inc. |
| LYEL – Lyell Immunopharma, Inc. |
Financial data and stock pages provided by
Fintel.io